SPRY
ARS Pharmaceuticals, Inc.
10.66
+0.07+0.66%
Dec 16, 4:00:00 PM EST

Upcoming Earnings 

Report date
-/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap
1.05B
P/E (TTM)
-
Basic EPS (TTM)
-0.81
Dividend Yield
0%

Recent Filings

About 

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

CEO
Mr. Richard E. Lowenthal M.B.A., M.S., MSMSEL
IPO
12/4/2020
Employees
162
Sector
Healthcare
Industry
Biotechnology